HOSPITAL UNIVERSITARIO RUBER
Departamento
Institut d'Investigació Biomédica de Bellvitge
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institut d'Investigació Biomédica de Bellvitge (7)
2023
-
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 67-80
-
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
The oncologist, Vol. 28, Núm. 1, pp. 23-32
2021
-
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
npj Precision Oncology, Vol. 5, Núm. 1
2019
-
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Aging, Vol. 11, Núm. 9, pp. 2874-2888
2017
-
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
Oncogene, Vol. 36, Núm. 19, pp. 2737-2749
2016
-
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308
2006
-
Vaccines against the human papillomavirus
Progresos en Obstetricia y Ginecologia, Vol. 49, Núm. 7, pp. 380-393